Marc Attiyeh

Dr. Marc Attiyeh

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2018 in Science
Verified
Journal Article
Closed access
PDF file
JRJohannes G. Reiter
Johannes G. Reiter
AMAlvin P. Makohon-Moore
Alvin P. Makohon-Moore
JGJeffrey M. Gerold
Jeffrey M. Gerold
AHAlexander Heyde
Alexander Heyde
MAMarc Attiyeh
Marc Attiyeh
MNMartin A. Nowak
Martin A. Nowak
Metastatic drivers same as primary: Treatment decisions for cancer patients are increasingly guided by analysis of the gene mutations that drive primary tumor growth. Relatively little is known about driver gene mutations in metastases, which cause most cancer-related deaths. Reiter et al. explored whether the growth of different metastatic lesions within an individual patient is fueled by the same or distinct gene mutations. In a study of 76 untreated metastases from 20 patients with different types of cancer, all metastases within a patient shared the same functional driver gene mutations. Thus, analysis of a single biopsy could help oncologists select the optimal therapy for patients with widespread metastatic disease. Science , this issue p. 1033

19 March 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
HSHitomi Sakamoto
Hitomi Sakamoto
MAMarc Attiyeh
Marc Attiyeh
JGJeffrey M. Gerold
Jeffrey M. Gerold
AMAlvin P. Makohon-Moore
Alvin P. Makohon-Moore
AHAkimasa Hayashi
Akimasa Hayashi
CIChristine A. Iacobuzio-Donahue
Christine A. Iacobuzio-Donahue
Surgery is the only curative option for stage I/II pancreatic cancer; nonetheless, most patients will experience a recurrence after surgery and die of their disease. To identify novel opportunities for management of recurrent pancreatic cancer, we performed whole-exome or targeted sequencing of 10 resected primary cancers and matched intrapancreatic recurrences or distant metastases. We identified that recurrent disease after adjuvant or first-line platinum therapy corresponds to an increased mutational burden. Recurrent disease is enriched for genetic alterations predicted to activate MAPK/ERK and PI3K–AKT signaling and develops from a monophyletic or polyphyletic origin. Treatment-induced genetic bottlenecks lead to a modified genetic landscape and subclonal heterogeneity for driver gene alterations in part due to intermetastatic seeding. In 1 patient what was believed to be recurrent disease was an independent (second) primary tumor. These findings suggest routine post-treatment sampling may have value in the management of recurrent pancreatic cancer. Significance: The biological features or clinical vulnerabilities of recurrent pancreatic cancer after pancreaticoduodenectomy are unknown. Using whole-exome sequencing we find that recurrent disease has a distinct genomic landscape, intermetastatic genetic heterogeneity, diverse clonal origins, and higher mutational burden than found for treatment-naïve disease. See related commentary by Bednar and Pasca di Magliano, p. 762. This article is highlighted in the In This Issue feature, p. 747

17 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
HLHeather J. Landau
Heather J. Landau
VYVenkata Yellapantula
Venkata Yellapantula
BDBenjamin T. Diamond
Benjamin T. Diamond
EREven H. Rustad
Even H. Rustad
KMKylee H. Maclachlan
Kylee H. Maclachlan
FMFrancesco Maura
Francesco Maura
Multiple myeloma (MM) progression is characterized by the seeding of cancer cells in different anatomic sites. To characterize this evolutionary process, we interrogated, by whole genome sequencing, 25 samples collected at autopsy from 4 patients with relapsed MM and an additional set of 125 whole exomes collected from 51 patients. Mutational signatures analysis showed how cytotoxic agents introduce hundreds of unique mutations in each surviving cancer cell, detectable by bulk sequencing only in cases of clonal expansion of a single cancer cell bearing the mutational signature. Thus, a unique, single-cell genomic barcode can link chemotherapy exposure to a discrete time window in a patient′s life. We leveraged this concept to show that MM systemic seeding is accelerated at relapse and appears to be driven by the survival and subsequent expansion of a single myeloma cell following treatment with high-dose melphalan therapy and autologous stem cell transplant.

8 October 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KMKatelyn M. Mullen
Katelyn M. Mullen
JHJungeui Hong
Jungeui Hong
MAMarc Attiyeh
Marc Attiyeh
AHAkimasa Hayashi
Akimasa Hayashi
HSHitomi Sakamoto
Hitomi Sakamoto
CIChristine A. Iacobuzio-Donahue
Christine A. Iacobuzio-Donahue
The genomic features of pancreatic ductal adenocarcinoma (PDAC) have been well described, yet the evolutionary contexts within which these features occur remain unexplored. We studied genome landscapes, phylogenies, and clonal compositions of 91 PDACs in relation to clinicopathologic features. There was no difference in the number of driver mutations or evolutionary timing when each mutation occurred. High truncal density, a metric of the accumulation of somatic mutations in the lineage that gave rise to each PDAC, was significantly associated with worse overall survival. Polyclonal, monoclonal, or mixed polyclonal/monoclonal metastases were identified across the cohort, highlighting multiple forms of intertumoral heterogeneity. Advanced stage and treated PDACs had higher odds of being polyclonal, whereas oligometastatic PDACs had fewer driver alterations, a lower fractional allelic loss, and increased likelihood of being monoclonal. In sum, our findings reveal novel insights into the dynamic nature of the PDAC genome beyond established genetic paradigms. Significance: Although the pancreatic cancer genome has been described, it has not been explored with respect to stages of diagnosis or treatment bottlenecks. We now describe and quantify the genomic features of PDAC in the context of evolutionary metrics and in doing so have identified a novel prognostic biomarker.

5 May 2020 in Human Pathology
Verified
Journal Article
Closed access
MAMarc Attiyeh
Marc Attiyeh
LZLance Zhang
Lance Zhang
CIChristine Iacobuzio-Donahue
Christine Iacobuzio-Donahue
PAPeter Allen
Peter Allen
RIRami Imam
Rami Imam
CSCarlie S. Sigel
Carlie S. Sigel

1 February 2018 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
VMVicente Morales-Oyarvide
Vicente Morales-Oyarvide
MMMari Mino-Kenudson
Mari Mino-Kenudson
CFCristina R. Ferrone
Cristina R. Ferrone
AWAndrew L. Warshaw
Andrew L. Warshaw
KLKeith D. Lillemoe
Keith D. Lillemoe
CCCarlos Fernández-Del Castillo
Carlos Fernández-Del Castillo